161 related articles for article (PubMed ID: 16187971)
1. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART.
Panhard X; Goujard C; Legrand M; Taburet AM; Diquet B; Mentré F;
Br J Clin Pharmacol; 2005 Oct; 60(4):390-403. PubMed ID: 16187971
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.
Hirt D; Treluyer JM; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Urien S
Antimicrob Agents Chemother; 2006 Jun; 50(6):2079-86. PubMed ID: 16723569
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
Crommentuyn KM; Scherpbier HJ; Kuijpers TW; Mathôt RA; Huitema AD; Beijnen JH
Pediatr Infect Dis J; 2006 Jun; 25(6):538-43. PubMed ID: 16732153
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.
Hirt D; Mentré F; Tran A; Rey E; Auleley S; Salmon D; Duval X; Tréluyer JM;
Br J Clin Pharmacol; 2008 Apr; 65(4):548-57. PubMed ID: 17922881
[TBL] [Abstract][Full Text] [Related]
5. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.
Hirt D; Urien S; Jullien V; Firtion G; Rey E; Pons G; Blanche S; Treluyer JM
Antimicrob Agents Chemother; 2006 Mar; 50(3):910-6. PubMed ID: 16495250
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy.
Brendel K; Legrand M; Taburet AM; Baron G; Goujard C; Mentré F;
Fundam Clin Pharmacol; 2005 Jun; 19(3):373-83. PubMed ID: 15910662
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.
Hirt D; Urien S; Jullien V; Firtion G; Chappuy H; Rey E; Pons G; Mandelbrot L; Treluyer JM
Br J Clin Pharmacol; 2007 Nov; 64(5):634-44. PubMed ID: 17892516
[TBL] [Abstract][Full Text] [Related]
8. Intracellular and plasma pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P-glycoprotein expression.
Ford J; Cornforth D; Hoggard PG; Cuthbertson Z; Meaden ER; Williams I; Johnson M; Daniels E; Hsyu P; Back DJ; Khoo SH
Antivir Ther; 2004 Feb; 9(1):77-84. PubMed ID: 15040539
[TBL] [Abstract][Full Text] [Related]
9. High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy.
Goujard C; Legrand M; Panhard X; Diquet B; Duval X; Peytavin G; Vincent I; Katlama C; Leport C; Bonnet B; Salmon-Céron D; Mentré F; Taburet AM;
Clin Pharmacokinet; 2005; 44(12):1267-78. PubMed ID: 16372824
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
Panhard X; Legrand M; Taburet AM; Diquet B; Goujard C; Mentré F;
Eur J Clin Pharmacol; 2007 Nov; 63(11):1019-29. PubMed ID: 17694300
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
[TBL] [Abstract][Full Text] [Related]
12. Ritonavir-enhanced pharmacokinetics of nelfinavir/M8 during rifampin use.
Bergshoeff AS; Wolfs TF; Geelen SP; Burger DM
Ann Pharmacother; 2003 Apr; 37(4):521-5. PubMed ID: 12659608
[TBL] [Abstract][Full Text] [Related]
13. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum.
van Heeswijk RP; Khaliq Y; Gallicano KD; Bourbeau M; Seguin I; Phillips EJ; Cameron DW
Clin Pharmacol Ther; 2004 Dec; 76(6):588-97. PubMed ID: 15592330
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women.
Villani P; Floridia M; Pirillo MF; Cusato M; Tamburrini E; Cavaliere AF; Guaraldi G; Vanzini C; Molinari A; degli Antoni A; Regazzi M
Br J Clin Pharmacol; 2006 Sep; 62(3):309-15. PubMed ID: 16934047
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
Crommentuyn KM; Kappelhoff BS; Mulder JW; Mairuhu AT; van Gorp EC; Meenhorst PL; Huitema AD; Beijnen JH
Br J Clin Pharmacol; 2005 Oct; 60(4):378-89. PubMed ID: 16187970
[TBL] [Abstract][Full Text] [Related]
17. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial.
Jackson KA; Rosenbaum SE; Kerr BM; Pithavala YK; Yuen G; Dudley MN
Antimicrob Agents Chemother; 2000 Jul; 44(7):1832-7. PubMed ID: 10858338
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications.
Bergshoeff AS; Fraaij PL; van Rossum AM; Wolfs TF; Geelen SP; de Groot R; Burger DM
Antivir Ther; 2003 Jun; 8(3):215-22. PubMed ID: 12924538
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Elisa test for therapeutic monitoring of Nelfinavir in HIV-positive patients.
Uglietti A; Genco F; Donadel E; Rinaldi S; Bastiani E; Maserati R; Meroni V
New Microbiol; 2007 Jul; 30(3):318-20. PubMed ID: 17802918
[TBL] [Abstract][Full Text] [Related]
20. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Payen S; Faye A; Compagnucci A; Giaquinto C; Gibbs D; Gomeni R; Bressolle F; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2005 Feb; 49(2):525-35. PubMed ID: 15673728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
